A company with its origins in scientific excellence

kv_1_4_geschichte

2017

  • Pipeline news: FYB202 is a biosimilar candidate for Stelara®
  • Formycon changes in new SME stock exchange segment “Scale”

2016

  • Focus magazine lists Formycon as growth champion 2017
  • German Stifterverband awards Formycon for innovative strength
  • Santo Holding (Deutschland) GmbH tranfers global commercialization rights for FYB201 to Bioeq IP AG
  • Dr. Carsten Brockmeyer again honored as one of the most influential people in medicines industry
  • Expansion of product pipeline with fourth biosimilar candidate
  • Details on FYB203: Formycon develops biosimilar for Eylea® (aflibercept)
  • Appointment of biotech expert Professor Johannes Buchner to Advisory Board
  • Enrollment of first patient in pivotal phase III study with Lucentis® biosimilar (FYB201)

2015

  • Formycon and bioeq initiate pivotal phase III clinical trial with Lucentis® biosimilar (FYB201)
  • Out-licensing of second biosimilar to Santo Holding
  • Medicine Maker: Dr. Carsten Brockmeyer under Top 20 in medicines industry
  • Capital increase of EUR 11.1 million
  • Successful GMP inspection

2014

  • Development of third product begins

2013

  • Successful completion of capital increase totaling EUR 17.5 million
  • Start of development of first and second product
  • Out-licensing of first biosimilar from Formycon product pipeline

2012

  • Renaming to Formycon AG
  • Leadership in the development of high-quality biopharmaceutical follow-up-products

2011

  • Scil Technology GmbH licenses its flagship project to Sanofi

2010

  • Scil Technology GmbH establishes a dedicated research and services unit under the name “Formycon”

2008

  • Scil Technology GmbH licenses project portfolio to Medtronic

2003

  • Alongside its own R&D projects, Scil Technology GmbH wins its first service-provider contracts, conducting its first biosimilar development projects on behalf of clients

2001

  • Analytical laboratory receives GMP certification

1999

  • Former executives of Boehringer Mannheim found Scil Technology GmbH